3,3-dimethyl-N-(3-methylbutyl)butanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3,3-dimethyl-N-(3-methylbutyl)butanamide
• 化学式: C₁₁H₂₃NO
• 分子量: 185.31
• InChiKey: PWNWEQMFLMPLQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT (ADC) AVEC DES INHIBITEURS DE NAMPT
  申请人：BAYER PHARMA AG

  公开号：WO2021013693A1

  公开（公告）日：2021-01-28

  Conjugate of a binder having formula (AA) wherein AB stands for a binder, Z' stands for a linker, D stands for an active component which is a NAMPT inhibitor and its use as pharmaceuticals.

  一个具有化学式（AA）的粘合剂的共轭物，其中AB代表粘合剂，Z'代表连接剂，D代表一种活性成分，即NAMPT抑制剂，并且其用作药物。
• ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20200138970A1

  公开（公告）日：2020-05-07

  The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型结合剂药物偶联物（ADCs），这些ADCs的活性代谢物，制备这些ADCs的过程，将这些ADCs用于治疗和/或预防疾病，以及将这些ADCs用于制备治疗和/或预防疾病的药物，特别是高增殖和/或血管生成异常等疾病，例如癌症等。这种治疗可以作为单独治疗，也可以与其他药物或其他治疗措施结合使用。
• Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US11071788B2

  公开（公告）日：2021-07-27

  The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型粘合剂药物共轭物（ADCs）、这些ADCs的活性代谢物、制备这些ADCs的工艺、使用这些ADCs治疗和/或预防疾病，以及使用这些ADCs制备治疗和/或预防疾病的药物，特别是过度增殖和/或血管生成性疾病，例如癌症。 这种治疗可以作为单一疗法，也可以与其他药物或进一步的治疗措施结合使用。
• DERIVES D'IMIDAZO-PYRIDINE COMME AGONISTES DU RECEPTEUR DE LA MELANCORTINE
  申请人：IPSEN PHARMA

  公开号：EP1615925B1

  公开（公告）日：2009-05-27
• PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS
  申请人：Bayer Aktiengesellschaft

  公开号：US20190351066A1

  公开（公告）日：2019-11-21

  The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which La, n, R and D have the definitions given in the description and which have a structural motif reduced to an asparagine derivative as cleavage site for tumour-associated proteases such as legumain, in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are released by legumain cleavage, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers. Reduction of the legumain-cleavable substrate peptide sequence to an asparagine derivative as structural motif, as a result of slowed legumain cleavage, achieves an increase in stability in the lysosomes of healthy organs while simultaneously maintaining the high anti-tumour effect.